BioWorld-International-2009-01-07
Genmab Shares Slide on Interim Zalutumumab Data
Genmab Shares Slide on Interim Zalutumumab Data
Shares in Genmab A/S were off by more than 7 percent during trading Tuesday following an interim update on a Phase III pivotal study of zalutumumab (HuMax-EGFr) in head and neck cancer. (BioWorld International)

